Education
About Us
Working with TipRanks
Follow Us
Suzhou Basecare Medical Corp. Ltd. Class H (HK:2170)
:2170
2170 Stock Chart & Stats
HK$1.97
HK$0.20(8.26%)
At close: 4:00 PM EST
HK$1.97
HK$0.20(8.26%)
Day’s Range― - ―
52-Week RangeHK$1.81 - HK$4.45
Previous CloseN/A
Volume107.50K
Average Volume (3M)121.73K
Market Cap
HK$503.29M
Enterprise ValueHK$236.01M
Total Cash (Recent Filing)HK$545.48M
Total Debt (Recent Filing)HK$342.23M
Price to Earnings (P/E)―
Beta1.33
Next Earnings
Mar 26, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.45
Shares Outstanding82,713,840
10 Day Avg. Volume98,950
30 Day Avg. Volume121,733
Financial Highlights & Ratios
PEG Ratio-0.12
Price to Book (P/B)0.62
Price to Sales (P/S)2.35
P/FCF Ratio-2.18
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue GrowthSustained ~11.4% revenue growth indicates expanding product adoption and market penetration. Over the next 2–6 months this underlying top-line momentum supports scale benefits, revenue visibility and provides a base to improve operating leverage if management tightens cost controls.
Product & R&D DiversificationA diversified portfolio across imaging, in vitro diagnostics and healthcare IT plus a stated R&D focus reduces single-product risk, enables cross-selling to hospitals and supports recurring service and maintenance revenue. This structural mix enhances resilience to demand shifts and fosters long-term competitiveness.
Balance Sheet LiquidityA solid equity ratio and available cash/short-term investments provide a financial buffer to fund operations, cover near-term obligations and support product development while management addresses profitability. This liquidity underpins strategic flexibility over the medium term.
Bears Say
Negative ProfitabilityPersistent negative net margins despite revenue growth signal structural cost issues (SG&A, R&D or scale inefficiencies). Without durable operating-cost reduction, the company will struggle to convert sales into sustainable profits and returns, limiting long-term shareholder value creation.
High LeverageElevated leverage raises refinancing, interest and covenant risks, particularly if cash generation remains weak. High debt constrains capital allocation, increases fixed costs and reduces resilience to shocks, making it harder to invest in R&D or absorb margin pressure over coming quarters.
Weak Cash GenerationOngoing negative operating cash flow indicates the core business does not reliably convert revenue into cash. This structural shortfall forces reliance on external financing, limits reinvestment capacity and elevates solvency risk unless operating cash conversion materially improves.
Suzhou Basecare Medical Corp. Ltd. Class H News
2170 FAQ
What was Suzhou Basecare Medical Corp. Ltd. Class H’s price range in the past 12 months?
Suzhou Basecare Medical Corp. Ltd. Class H lowest stock price was HK$1.81 and its highest was HK$4.45 in the past 12 months.
What is Suzhou Basecare Medical Corp. Ltd. Class H’s market cap?
Suzhou Basecare Medical Corp. Ltd. Class H’s market cap is HK$503.29M.
When is Suzhou Basecare Medical Corp. Ltd. Class H’s upcoming earnings report date?
Suzhou Basecare Medical Corp. Ltd. Class H’s upcoming earnings report date is Mar 26, 2026 which is in 31 days.
How were Suzhou Basecare Medical Corp. Ltd. Class H’s earnings last quarter?
Suzhou Basecare Medical Corp. Ltd. Class H released its earnings results on Aug 29, 2025. The company reported -HK$0.453 earnings per share for the quarter, beating the consensus estimate of -HK$3.126 by HK$2.674.
Is Suzhou Basecare Medical Corp. Ltd. Class H overvalued?
According to Wall Street analysts Suzhou Basecare Medical Corp. Ltd. Class H’s price is currently Overvalued.
Does Suzhou Basecare Medical Corp. Ltd. Class H pay dividends?
Suzhou Basecare Medical Corp. Ltd. Class H does not currently pay dividends.
What is Suzhou Basecare Medical Corp. Ltd. Class H’s EPS estimate?
Suzhou Basecare Medical Corp. Ltd. Class H’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Suzhou Basecare Medical Corp. Ltd. Class H have?
Suzhou Basecare Medical Corp. Ltd. Class H has 82,713,840 shares outstanding.
What happened to Suzhou Basecare Medical Corp. Ltd. Class H’s price movement after its last earnings report?
Suzhou Basecare Medical Corp. Ltd. Class H reported an EPS of -HK$0.453 in its last earnings report, beating expectations of -HK$3.126. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Suzhou Basecare Medical Corp. Ltd. Class H?
Currently, no hedge funds are holding shares in HK:2170
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Suzhou Basecare Medical Corp. Ltd. Class H Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-37.08%
12-Months-Change
Fundamentals
Return on Equity
-20.60%
Trailing 12-Months
Asset Growth
-11.13%
Trailing 12-Months
Company Description
Suzhou Basecare Medical Corp. Ltd. Class H
Suzhou Basecare Medical Corporation Limited, an investment holding company, engages in the research, development, manufacture, and provision of genetic testing solutions for assisted reproduction and sale of genetic testing devices and instruments in the People's Republic of China. The company offers genetic test kit products, which include pre-implantation genetic test kits, such as PGT-A to detect aneuploidy; PGT-M to detect single-gene or monogenic defects in pre-implantation embryos; and PGT-SR kits to detect chromosome structural rearrangements, which are common causes of recurrent miscarriage. It also provides prenatal test kit products comprising CNV kits; postnatal test kit products consist of WES kits; and devices and instruments, including liquid nitrogen storage dewar, cryostorage system, automated workstation, sperm quality analyzer, and NGS sequencer. The company also engages in the research, development, manufacture, and sale of medical devices and instruments. In addition, it provides marketing services; and engages in the research and development of software for medical devices and instruments. The company serves hospitals and reproductive clinics. Suzhou Basecare Medical Corporation Limited was incorporated in 2010 and is headquartered in Suzhou, China.
Technical Analysis
Peijia Medical Ltd.
―
MicroPort CardioFlow Medtech Corp.
―
Broncus Holding Corp.
―
MicroTech Medical (Hangzhou) Co., Ltd. Class H
―
Venus Medtech (Hangzhou), Inc. Class H
―